共 50 条
- [42] Subsequent therapies after progressing to CDK4/6 inhibition (CDK4/6i) in hormone receptor positive/HER2 negative (HR+/HER2-) advanced breast cancer (ABC)ANNALS OF ONCOLOGY, 2021, 32 : S69 - S70Laguna, J. C.Braso-Maristany, F.Pascual, T.Rodriguez Hernandez, A.Chic, N.Schettini, F.Sanfeliu Torres, E.Gonzalez-Farre, B.Martinez, D.Galvan, P.Diez-Guardia, V.Adamo, B.Vidal, M.Guillen Sacoto, M. C.Moreno, R.Prat, A.Munoz, M.Martinez-Saez, O.
- [43] Resistance to CDK4/6 inhibition: Mechanisms and strategies to overcome a therapeutic problem in the treatment of hormone receptor-positive metastatic breast cancerBIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2022, 1869 (12):Papadimitriou, Marios C.Pazaiti, AnastasiaIliakopoulos, KonstantinosMarkouli, MariamMichalaki, VasilikiPapadimitriou, Christos A.
- [44] RET inhibition overcomes resistance to combined CDK4/6 inhibitor and endocrine therapy in ER plus breast cancerFRONTIERS IN ONCOLOGY, 2025, 14Kindt, Charlotte K.Ehmsen, SidseTraynor, SofiePolicastro, BenedettaNissen, NikolineJakobsen, Mie K.Hundebol, Monique F.Johansen, Lene E.Bak, MartinArbajian, ElsaStaaf, JohanDitzel, Henrik J.Alves, Carla L.
- [45] Combined inhibition of CDK4/6 and AKT is highly effective against the luminal androgen receptor (LAR) subtype of triple negative breast cancerCANCER LETTERS, 2024, 604Chica-Parrado, Maria RosarioKim, Gun MinUemoto, YasuakiNapolitano, FabianaLin, Chang-ChingYe, DanBikorimana, EmmanuelFang, YishengLee, Kyung-minMendiratta, SaurabhHanker, Ariella B.Arteaga, Carlos L.
- [46] Inhibition of METTL14 overcomes CDK4/6 inhibitor resistance driven by METTL14-m6A-E2F1-axis in ERα-positive breast cancerJOURNAL OF NANOBIOTECHNOLOGY, 2025, 23 (01)Liu, ChenlinFan, DongSun, JiahuiLi, GuodongDu, RuoxinZuo, XiaoshuangZhang, KuoZhang, WangqianWang, ShuningLi, XiaojvDu, MingruiWang, DonghuiHao, QiangZhang, YingqiLi, MengZhang, CunGao, Yuan
- [47] Is there a role for continuation of CDK4/6 inhibition after progression on a prior CDK4/6 inhibitor in HRD/HER2L metastatic breast cancer?ANNALS OF ONCOLOGY, 2024, 35 (01) : 10 - 14Giordano, A.Lin, N. U.Tolaney, M.Mayer, L.
- [48] Inhibiting eIF4E phosphorylation sensitizes triple-negative breast cancer to CDK4/6 inhibitionMOLECULAR CANCER THERAPEUTICS, 2024, 23 (06)Deng, QiyunAmiri, MehdiPiric, Anastasija AnaBagherian, YasamanLi, ZilanHuang, SidongPollak, MichaelSonenberg, Nahum
- [49] In Prostate Cancer C/EBPα Promotes Cell Growth by the Loss of Interactions With CDK2, CDK4, and E2F and by Activation of AKTPROSTATE, 2009, 69 (09): : 1001 - 1016Yin, HongLowery, MaryGlass, Jonathan
- [50] Dual Targeting of CDK4/6 and BCL2 Pathways Augments Tumor Response in Estrogen Receptor-Positive Breast CancerCLINICAL CANCER RESEARCH, 2020, 26 (15) : 4120 - 4134Whittle, James R.Vaillant, FrancoisSurgenor, ElliotPolicheni, Antonia N.Giner, GoknurCapaldo, Bianca D.Chen, Huei-RongLiu, He K.Dekkers, Johanna F.Sachs, NormanClevers, HansFellowes, AndrewGreen, ThomasXu, HuilingFox, Stephen B.Herold, Marco J.Smyth, Gordon K.Gray, Daniel H. D.Visvader, Jane E.Lindeman, Geoffrey J.